Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalbán, Bruce Cree, Nadia Tenenbaum et al.|The Lancet Neurology|2024Cited by 74